Dogwood Therapeutics Q3 2025 net loss $15.7M; cash runway through Q1 2026

Dogwood Therapeutics, Inc.

2025-Q3 EPS reported -$18.02 vs consensus -$1.25 ▼ miss (-1342.2%)

Net loss per share of $8.20 vs. $2.05 in Q3 2024; R&D expenses surged to $14.5M from $0.5M.
100 patients enrolled, 80 completed in Halneuron Phase 2b trial; interim analysis on track for Q4 2025.
Secured exclusive worldwide royalty-free license to develop SP16 for cancer-related pain via all-stock transaction.
Cash and equivalents of $10.1M expected to fund operations into Q1 2026.
SP16 Phase 1b study fully funded by National Cancer Institute; FDA feedback anticipated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.